Bayer Pharma Aktiengesellschaft

Bayer Aktiengesellschaft

The Broad Institute, Inc.

Dana-farber-cancer Institute Inc.

Max-delbruck-centrum Fur Molekulare Medizin in Der Helmholtz-gemeinschaft

Ulrike Sack

Philip Lienau

Nicolas Werbeck

Clara Christ

Knut Eis

Ulrich Klar

Christopher G Nasveschuk

Ulrich Lücking

Michael H Serrano-Wu

Kai Thede

Joachim Kuhnke

Matthew Meyerson

Kiel Lazarski

Philipp Buchgraber

Steven James Ferrara

Sarah Anna Liesa Johannes

Heidi Greulich

David A McKinney

Patrick Ryan McCarren

Mark A Fitzgerald

Guo Wei

Laura Furst

Xiaoyun Wu

Alex Burgin

Franziska Siegel

Daniel Hog

Luc De Waal

Monica Schenone

Arne Scholz

Antje Margret Wengner

Ursula Mönning

Timothy A Lewis

Amaury Ernesto Fernandez-Montalvan

Martin Lange

Chris A Lemke

Manfred Moewes

Anne Mengel

Stefan Kaulfuss

Ursula Moenning

Manfred Möwes

Wolfgang Walther

Peter Michael Schlag

Ulrike Stein

Dominic Scudiero

Christopher Lemke

Amaury Fernandez-Montalvan

Katrin Nowak-reppel

Amaury Ernesto Fernandez-montalvan

Ursula Monning

David Mckinney

Mark Fitzgerald

Patrick Ryan Mccarren

Chris Lemke

Manfred Mowes

Christopher Nasveschuk

Philipp Lienau

Robert Shoemaker

The present invention features improved compounds, especially methods of identifying patients having cancer using biomarkers (e.g., PDE3A, SLFN12 and/or CREB3L1) that correlate with drug sensitivity and consequently treating a stratified patient population with an agent of the invention (e.g., Compounds 1-6 disclosed herein).

Compounds, compositions and methods for cancer patient stratification and cancer treatment

The present invention relates to novel modified macrocyclic compounds with improved tolerability of general formula (I) as described and defined herein, and methods for their preparation, their use for the treatment and/or prophylaxis of disorders, in particular of hyper-proliferative disorders and/or virally induced infectious diseases and/or of cardiovascular diseases. The invention further relates to intermediate compounds useful in the preparation of said compounds of general formula (I).

PTEFB inhibiting macrocyclic compounds

The present invention relates to macrocyclic indole derivatives of general formula (I) in which R, R, R, R, R, R, A and L are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds, and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular of hyperproliferative disorders, as a sole agent or in combination with other active ingredients.

Macrocyclic indole derivatives

A method for inhibiting, reducing and/or reducing the risk of cancer metastasis in a subject, including identifying a subject as in need of inhibiting, reducing and/or reducing the risk of cancer metastasis, by identifying the subject as having a cancer with an elevated or up-regulated level of S100A4 transcription compared to a level in non-oncogenic cells, and administering to the subject a therapeutically effective amount of niclosamide or a niclosamide derivate, thereby inhibiting or reducing S100A4 transcription, so as to inhibit, reduce and/or reduce the risk of cancer metastasis, wherein 15 to 400 mg niclosamide or niclosamide derivate is administered per kg body weight of the subject (mg/kg), 1 or 2 times daily.

Niclosamide for the treatment of cancer metastasis

The present invention relates to macrocyclic indole derivatives of general formula (I): in which R, R, R, R, R, R, A and L are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds, and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular of hyperproliferative disorders, as a sole agent or in combination with other active ingredients.

Macrocyclic fluorine substituted indole derivatives

The present invention relates to novel modified macrocyclic compounds with improved tolerability of general formula (I) as described and defined herein, and methods for their preparation, their use for the treatment and/or prophylaxis of disorders, in particular of hyper-proliferative disorders and/or virally induced infectious diseases and/or of cardiovascular diseases. The invention further relates to intermediate compounds useful in the preparation of said compounds of general formula (I). 

PTEFb inhibiting macrocyclic compounds

The present invention features improved methods of identifying patients having cancer (e.g., melanoma, adenocarcinoma, lung, cervical, liver or breast cancer) using biomarkers (e.g., PDE3A, SLFN12) that correlate with drug sensitivity and consequently treating a stratified patient population with an agent of the invention (e.g., DNMDP, zardaverine, and anagrelide).

Compositions and methods for cancer expressing PDE3A or SLFN12

The present invention relates to macrocyclic indole derivatives of general formula (I): in which R, R, R, R, R, R, A and L are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds, and the use of said compounds for manufacturing pharmaceutical 2019 compositions for the treatment or prophylaxis of diseases, in particular of hyperproliferative disorders, as a sole agent or in combination with other active ingredients.

The present invention features improved Compounds, especially (I) methods of identifying patients having Cancer using biomarkers (e.g., PDE3A, SLFN12 and/or CREB3L1) that correlate with drug sensitivity and consequently treating a stratified patient population with an agent of the invention (e.g., Compounds 1-6 disclosed herein). 

Growing community of inventors

Berlin, Germany

Ulrike Sack